Autoimmunity | Pharmacokinetics & Drug Delivery | Immunopharmacology & Hematologic Pharmacology | Clinical Immunology | Methods for Diagnostic & Therapeutic Studies
Increased frequency of infections at the end of the IVIG dosing cycle: effect characterization from three Phase III studies
Martin Bexon, Jeffrey S Baggish*, Mikhail A Rojavin, Melvin Berger, Othmar Zenker
*Corresponding author: Jeffrey S Baggish
CSL Behring LLC, King of Prussia, PA, USA
F1000Posters 2012, 3: 373 (poster) [English]
Poster [2.73 MB]
American College of Allergy, Asthma & Immunology Annual Scientific Meeting 2012, 8 - 13 Nov 2012, 730
Patients with primary immunodeficiencies (PI) are predisposed to frequent infections and require life-long, regular infusions of IgG. Intravenous IgG (IVIG) therapy, given at 3- or 4-week intervals, is widely used in patients with PI and is the standard of care. Intravenous infusions of IgG products produce an immediate, sharp rise in serum IgG levels, which decline as IgG redistributes into the extravascular space over the following 48 hours, and then fall with first-order kinetics over approximately 3 weeks. A regimen with dosing every 3-4 weeks results in substantial IgG concentration variations rather than a steady state. Towards the end of the dosing cycle, serum IgG levels may drop below the protective level.
This pooled analysis supports in an objective manner the “wear-off” effect observed in patients receiving IVIG infusions at 3-4 week intervals.
The “wear-off” effect observed in this assessment is likely due to the low IgG trough levels associated with infrequent IVIG administration; however, additional investigations are needed to further support this hypothesis.
All authors are employees of CSL Behring.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License